Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations

@inproceedings{Ihle2013ComparisonOH,
  title={Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations},
  author={Michaela Angelika Ihle and Jana Fassunke and Katharina Koenig and Inga Gr{\"u}newald and Max Schlaak and Nicole Kreuzberg and Lothar Tietze and Hans-Ulrich Schildhaus and Reinhard H Buettner and Sabine Merkelbach-Bruse},
  booktitle={BMC Cancer},
  year={2013}
}
The approval of vemurafenib in the US 2011 and in Europe 2012 improved the therapy of not resectable or metastatic melanoma. Patients carrying a substitution of valine to glutamic acid at codon 600 (p.V600E) or a substitution of valine to leucine (p.V600K) in BRAF show complete or partial response. Therefore, the precise identification of the underlying somatic mutations is essential. Herein, we evaluate the sensitivity, specificity and feasibility of six different methods for the detection of… CONTINUE READING